| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
14 |
| Employees |
253 |
| Revenues (TTM) (Millions $) |
81 |
| Net Income (TTM) (Millions $) |
-320 |
| Cash Flow (TTM) (Millions $) |
-47 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Melinta Therapeutics, Inc. is a pharmaceutical company headquartered in New Haven, Connecticut, USA. The company was founded in 2000 and specializes in the development and commercialization of antibiotics for the treatment of serious and often life-threatening bacterial infections. It aims to address the growing public health crisis of antibiotic resistance.
Melinta's portfolio of antibiotics includes products that target gram-positive, gram-negative, and anaerobic bacteria. Its lead product is Baxdela (delafloxacin), which was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria, as well as community-acquired bacterial pneumonia (CABP). Melinta also has a pipeline of next-generation antibiotics under development, including berdelisitinib, an investigational oral antibiotic for the treatment of urinary tract infections.
The company has two commercial units, one focused on acute care hospitals and the other on long-term care facilities, and is also working to expand its reach globally. In addition to its commercial activities, Melinta is also involved in research and development efforts in collaboration with academic institutions, government agencies, and pharmaceutical companies.
Melinta has faced some financial difficulties in recent years, including bankruptcy in 2020, but emerged from it with new leadership and strategic focus. It has since renewed its efforts to advance its pipeline and commercialize its existing products to address the growing need for novel antibiotics.
Overall, Melinta Therapeutics, Inc. has emerged as a significant player in the field of infectious disease therapeutics, with an unparalleled focus on development of antibiotics for serious and often life-threating bacterial infections affecting diverse populations globally.
|
%